ASH: Treanda (bendamustine)
ASH platform presentations provide the latest data from company-sponsored Phase 2 multi-center registration studies on two Cephalon Oncology investigational compounds, TREANDA(R) (bendamustine HCL) and CEP-701 (lestaurtinib).
TREANDA is a novel alkylating-benzimidazole hybrid cytotoxic in which a molecular ring common to traditional alkylators is altered. Preclinical research provides evidence that TREANDA induces efficient and durable cell damage.
Bendamustine has been available in Germany for more than three decades for several indications, including NHL, chronic lymphocytic leukemia, multiple myeloma, and several solid tumors.
Source: www.cephalon.com
TREANDA is a novel alkylating-benzimidazole hybrid cytotoxic in which a molecular ring common to traditional alkylators is altered. Preclinical research provides evidence that TREANDA induces efficient and durable cell damage.
Bendamustine has been available in Germany for more than three decades for several indications, including NHL, chronic lymphocytic leukemia, multiple myeloma, and several solid tumors.
Source: www.cephalon.com
posted by gwg at 8:32 PM
0 Comments:
Post a Comment
<< Home